financetom
Business
financetom
/
Business
/
SBA Communications Q1 Adjusted FFO Rises, Revenue Falls; Sets 2024 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SBA Communications Q1 Adjusted FFO Rises, Revenue Falls; Sets 2024 Outlook
Apr 29, 2024 2:12 PM

04:55 PM EDT, 04/29/2024 (MT Newswires) -- SBA Communications ( SBAC ) reported Q1 adjusted funds from operations late Monday of $3.29 per share, up from $3.13 a year earlier.

Analysts polled by Capital IQ forecast $3.29.

Revenue for the quarter ended March 31 was $657.9 million, down from $675.5 million a year earlier.

Analysts surveyed by Capital IQ projected $669.9 million.

The company said it now expects a full-year 2024 adjusted FFO of $13.09 to $13.46 per share. Analysts polled by Capital IQ expect $13.35.

Revenue for the year is now projected to be in the range of $2.66 billion to $2.7 billion. Analysts surveyed by Capital IQ expect $2.69 billion.

The company said its board kept the quarterly dividend at $0.98 per share, payable June 19 to shareholders of record on May 23.

Shares of the company were down 2% in after-hours trading.

Price: 197.85, Change: -4.04, Percent Change: -2.00

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pfizer Reports Encouraging Long-Term Trial Results of Advanced Lung Cancer Drug
Pfizer Reports Encouraging Long-Term Trial Results of Advanced Lung Cancer Drug
May 31, 2024
01:21 PM EDT, 05/31/2024 (MT Newswires) -- Pfizer ( PFE ) said Friday its Lorbrena drug for an advanced form of lung cancer helped patients live longer without disease progression, based on long-term follow-up results of a late-stage trial. Roughly 60% of patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer and treated with Lorbrena were alive without disease...
CAE Ratings Affirmed by S&P
CAE Ratings Affirmed by S&P
May 31, 2024
01:17 PM EDT, 05/31/2024 (MT Newswires) -- S&P Global Ratings on Friday affirmed its ratings on CAE (CAE.TO), including its BBB- issuer credit rating on the company. The rating affirmation comes after CAE reported a re-baselining of its defense business, along with defense impairment charges and contract adjustments related to eight previously identified fixed-price legacy contracts. The stable outlook reflects...
Fairfax Financial Holdings' Re/Insurance Subs Upgraded by S&P
Fairfax Financial Holdings' Re/Insurance Subs Upgraded by S&P
May 31, 2024
01:16 PM EDT, 05/31/2024 (MT Newswires) -- S&P Global Ratings said Friday that it upgraded ratings on Fairfax Financial Holdings' ( FRFHF ) core re/insurance subsidiaries to A+ from A and on the holding company, Fairfax Financial Holdings ( FRFHF ) to BBB+ from BBB. The upgrade follows S&P's revised criteria for analyzing insurers' risk-based capital. The implementation of the...
Moderna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine
Moderna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine
May 31, 2024
On Friday, the FDA approved Moderna Inc’s mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine to protect adults aged 60 and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna ( MRNA ), the first being the famed COVID-19 vaccine....
Copyright 2023-2026 - www.financetom.com All Rights Reserved